Phase 2/3 data show sustained hair growth and favorable safety outcomes with oral VDPHL01 in men with androgenetic alopecia.

At a Dermatology Times Case-Based Roundtable event, Carolyn Goh, MD, led clinicians through a discussion of severity scoring, patient-reported outcomes, CYP2C9 testing, and long-term monitoring across 3 alopecia areata cases.

Houston dermatology clinicians compared severity scoring, JAK inhibitor safety data, and psychosocial counseling strategies across 3 alopecia areata patient cases.

The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.